Pulmatrix, Inc.
Pulmatrix, Inc. is a U.S.-based biopharmaceutical company focused on developing inhaled therapeutic products using its patented iSPERSE™ dry powder delivery platform. Its pipeline has included product candidates for respiratory diseases and central nervous system disorders, with development centered on improving how drugs are delivered to the lungs.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueEngineered dry powder technology used to formulate and deliver inhaled drugs.
Inhaled product candidates aimed at serious lung diseases such as COPD and ABPA.
Inhaled candidates intended for central nervous system disorders such as acute migraine.
Programs advanced with collaborators or monetized through licensing and royalties.
Customers
Pulmatrix does not currently sell approved products; its economic model is centered on partnering with pharmaceutical companies, licensing its technology, and advancing product candidates through development. The main counterparties are potential licensees, development partners, CROs, and CMOs that support clinical and manufacturing work. If products are approved in the future, customers would be patients and healthcare providers in respiratory and migraine treatment markets.
Companies that may license iSPERSE or co-develop inhaled candidates to access the platform and pipeline.
CROs and CMOs that perform trials, formulation work, and manufacturing for the pipeline.
Patients and clinicians in respiratory and migraine markets who would use approved inhaled therapies.
Potential buyers of assets or the company seeking to monetize the platform or clinical programs.
Strategy
Pulmatrix’s strategy is to monetize iSPERSE and its clinical assets through partnerships, licensing, asset sales, or other strategic transactions. The company also seeks to preserve optionality for its inhaled pipeline by advancing candidates only when funding and collaboration support are available. This approach is designed to reduce the capital burden of late-stage drug development while keeping the platform available for external commercialization.
The platform is the core proprietary asset and the main source of potential value creation.
Clinical candidates may still have value if funding or partner support becomes available.
A transaction could provide a path to realize value from the company or its assets.
Geography
Pulmatrix is incorporated in Delaware and maintains a mailing address in Framingham, Massachusetts, while operating as a virtual company without owned or leased physical facilities. Its development and partnering activities are tied to the United States, with partnered clinical development and potential commercialization extending outside the U.S. through collaborators such as Cipla. Geography matters because the company depends on cross-border regulatory approvals, partner execution, and access to specialized clinical and manufacturing vendors.
Risks
Pulmatrix faces the typical risks of an early-stage biopharmaceutical company: clinical failure, regulatory delay, dependence on third parties, and the need for additional capital. Its value is also exposed to transaction execution risk because monetization of the platform or assets depends on successful partnering, asset sales, or other strategic outcomes.
- Financing riskImpact: HighLikelihood: High
The company expects to need additional capital to continue operations.
Exposure: R&D and G&A funding
- Clinical development failureImpact: HighLikelihood: Medium
Product candidates must succeed in testing before they can be commercialized.
Exposure - Regulatory approval riskImpact: HighLikelihood: Medium
The company cannot market products without FDA or foreign approvals.
Exposure: Respiratory and migraine programs
- Third-party execution riskImpact: HighLikelihood: Medium
Clinical trials and manufacturing are outsourced to CROs and CMOs.
Exposure: Clinical development and supply chain
- Transaction and monetization riskImpact: MediumLikelihood: Medium
Value realization depends on successful partnering, merger, or asset sale.
Exposure: Strategic alternatives and merger process
- Cybersecurity and data protection riskImpact: MediumLikelihood: Low
Clinical, supplier, and employee data could be disrupted or compromised.
Exposure: IT systems and third-party interfaces
Accounting
Judgemental itemsPast revenue came primarily from the Cipla agreement, so contract timing affects reported revenue.
Impact: Can create lumpy revenue tied to milestones or wind-down activities
Most development and manufacturing support costs are expensed as incurred.
Impact: Drives operating loss profile and comparability across periods
Strategic alternatives or asset monetization may require write-downs or gain/loss recognition.
Impact: Could materially affect reported results in transaction periods
Tax assets depend on future taxable income and may be limited by ownership changes.
Impact: Affects deferred tax asset realizability
Similar listed companies
Publicly listed companies with a comparable business focus.
Pulmonx Corp
LUNG · Surgical & Medical Instruments & Apparatus
Pulmonx Corp is a U.S.-based medical device company focused on minimally invasive treatments for severe emphysema and other advanced chronic obstructive pulmonary disease (COPD) patients.
Ispire Technology Inc.
ISPR · Cigarettes
Theravance Biopharma, Inc.
TBPH · Pharmaceutical Preparations
Theravance Biopharma is a U.S.-based biopharmaceutical company focused on developing and commercializing medicines for respiratory and other specialty indications.
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB · Pharmaceutical Preparations
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company focused on developing rademikibart, an antibody designed to target IL-4Rα for asthma and COPD.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Last updated: 24/09/2026